ALSO NOTED: Teva loses out on Celebrex copycat; Wyeth to build $280M plant in China;

> Switzerland's Cytos stirred up some excitement with its announcement that new trial data backs up its hopes for a new vaccine that can be used to thwart high blood pressure. Report

> A federal appeals court tossed out one of Pfizer's three patents on the painkiller Celebrex, but upheld a lower court's decision that ruled out a copycat version from Teva Pharmaceutical Industries because it would infringe on the remaining two. The ruling would keep Teva's generic off the market till 2015. Report | Report

> Wyeth plans to spend $280 million to build a plant in China that will make mostly infant formula and nutritional products for the regional market; when complete in 2010, it's expected to employ 300. Release

> Immunicon plans to cut 45 of its 100 workers after a dispute over the marketing of its CellSearch cancer test with Veridex, a Johnson & Johnson unit. Report

> Eleven drug makers have agreed to pay $125 million over average wholesale prices after a lawsuit charged that consumers and payors paid more than they should have because of false reporting. The new settlement includes Abbot, Amgen, Sanofi-Aventis, Baxter, Bayer, and others. Report

> The FDA gave its nod for Spectrum Pharmaceuticals' oncology drug Levoleucovorin; the company expects to launch by June. Report

> Cepheid is cashing in on MRSA trends--for now. Report

And Finally... Who keeps drug-sample inventories and rides herd on departing sales reps? Sports trainers. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.